Sex Steroids and Lipoproteins

  • Valery T. Miller
  • John C. La Rosa

Abstract

For women the use of exogenous sex steroids is taking on an importance beyond the areas of sexual development, contraception, fertility, and menopausal symptom relief. Appropriate use of estrogens and progestogens at different times in a woman’s life may have the potential to either accelerate or prevent atherosclerotic heart disease. 1,2 Because in women, as in men, heart disease is the number one cause of death, physicians caring for women must understand how sex steroids influence death and disability due to heart disease.3

Keywords

Cholesterol Osteoporosis Lipase Progesterone Triglyceride 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Stadel BV. Oral contraceptives and cardiovascular disease. N Engl J Med 1981;305:612–118.PubMedCrossRefGoogle Scholar
  2. 2.
    Bush TL, Barrett-Connor E, Cowan LD, et al. Cardiovascular mortality and noncontraceptive use of estrogen in women: results from the Lipid Research Clinic Program’s Follow-up Study. Circulation 1967;75:1102–1109.CrossRefGoogle Scholar
  3. 3.
    Vital Statistics of the United States, 1981. Mortality Part A, 1986. Hyattsville, MD: National Center for Health Statistics, 1986. Google Scholar
  4. 4.
    Mandel FP, Geola FL, Lu JKH, et al. Biologic effects of various doses of ethinyl estradiol in postmenopausal women. Obstet Gynecol 1982;59:673–678.PubMedGoogle Scholar
  5. 5.
    Mandel FP, Geola FL, Medrum DR, et al. Biological effects of various doses of vaginally administered conjugated equine estrogens in postmenopausal estrogen. J Clin Endocrinol Metab 1983;57:133–137.PubMedCrossRefGoogle Scholar
  6. 6.
    Maschak CA, Lobo RA, Dozono-Takano R, et al. Comparison of pharmacodynamic properties of various estrogen formulations. Am J Obstet Gynecol 1982;144:511–518.Google Scholar
  7. 7.
    Frumar AM, Geola F, Tataryn IV, et al. Biological effects of estrogen at different sites of action in postmenopausal women. In: Scientific Abstracts, Twenty-sixth Annual Meeting of the Society for Gynecological Investigation, San Diego, 1979:66. Google Scholar
  8. 8.
    Geola FL, Frumar AM, Tataryn IV, et al. Biological effects of various doses of conjugated equine estrogens in postmenopausal women. J Clin Endocrinol Metab 1980;51:620–625.PubMedCrossRefGoogle Scholar
  9. 9.
    Goebelsmann U, Maschak CA, Mishell DR. Comparison of hepatic impact of oral and vaginal administration of ethinyl estradiol. Am J Obstet Gynecol 1985;151:868–877.PubMedGoogle Scholar
  10. 10.
    Lobo RA. Absorption and metabolic effects of different types of estrogens and progestogen. Obstet Gynecol Clin North Am 1987;14:143–165.PubMedGoogle Scholar
  11. 11.
    Jensen J, Riis BJ, Str0m V, et al. Longterm effects of percutaneous estrogen and oral progesterone on serum lipoproteins in menopausal women. Am J Obstet Gynecol 1987;156:66–71.PubMedGoogle Scholar
  12. 12.
    Lobo RA, March CM, Goebelsmann UT, et al. Subdermal estradiol pellets following hysterectomy and oophorectomy. Am J Obstet Gynecol 1980; 138:714–719.PubMedGoogle Scholar
  13. 13.
    Stanczyk FZ, Shoupe D, Nunez V, et al. A randomized comparison of ethinyl estradiol delivery in postmenopausal women. Am J Obstet Gynecol 1988;159:1540–1546.PubMedGoogle Scholar
  14. 14.
    Bush TL, Miller VT. Effects of pharmocologic agents used during the menopause, In: Mishell DR Jr, ed. Menopause: Physiology and Pharmacology. Chicago: Year Book Medical Publishers, 1987:187–208.Google Scholar
  15. 15.
    Cheung MD, Albers JJ. The measurement of apolipoprotein A-I and A-II levels in men and women by immunoassay. J Clin Invest 1977;60:43–50.PubMedCrossRefGoogle Scholar
  16. 16.
    Gordon T, Castelli WP, Hjortland MC, et al. High density apoprotein as a protective factor against coronary heart disease. Am J Med 1977;62:707–714.PubMedCrossRefGoogle Scholar
  17. 17.
    Kannel WB, Castelli WP, Gordon T, et al. Serum cholesterol, lipoproteins and the risk of coronary diseases: the Framingham Study. Ann Intern Med 1971; 74:1–12.PubMedGoogle Scholar
  18. 18.
    Abbot RD, Wilson PWF, Kannel WP, et al. High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction: the Framingham Study. Arteriosclerosis 1988;8:207–211.CrossRefGoogle Scholar
  19. 19.
    Kannel WB, D’Agostino RB, Belanger AJ. New insights on cholesterol-lipoprotein profiles: the Framingham Study. Presented at the 61st Scientific Sessions of the AHA, November 1988. Google Scholar
  20. 20.
    Freedman DS, Gruchow HW, Anderson AJ, et al. Relation of triglyceride levels to coronary artery disease: the Milwaukee cardiovascular data registry. Am J Epidemiol 1988;127:1118–1130.PubMedGoogle Scholar
  21. 21.
    Schaefer EJ, Foster DM, Zech LA, et al. The effects of estrogen administration on plasma lipoprotein metabolism in premenopausal females. J Clin Endocrinol Metab 1983;57:262–267.PubMedCrossRefGoogle Scholar
  22. 22.
    Bradley DD, Wingerd J, Petitti DB, et al. Serum high density lipoprotein cholesterol in women using oral contraceptives, estrogen and progestin. N Engl J Med 1978;299:17–20.PubMedCrossRefGoogle Scholar
  23. 23.
    Applebaum DM, Goldberg AP, Pykalisto OJ, et al. Effect of estrogen on post-heparin lipolytic activity; selective decline in hepatic triglyceride lipase. J Clin Invest 1977;59:601–608.PubMedCrossRefGoogle Scholar
  24. 24.
    Wahl P, Walden C, Knopp R, et al. Effect of estrogen/progestin potency on lipid and lipoprotein cholesterol. N Engl J Med 1983;308:862–867.PubMedCrossRefGoogle Scholar
  25. 25.
    Kovanen PT, Brown MS, Goldstein JL. Increased binding of low-density lipoprotein to liver membrane from rats treated with 17 alpha-ethinyl estradiol. J Biol Chem 1979;254:1367–1373.Google Scholar
  26. 26.
    Brenner PF. The pharmacology of progestogens. J Reprod Med 1982:27:490–497.PubMedGoogle Scholar
  27. 27.
    Runnebaum B, Rabe TR. New progestogens in oral contraceptives. Am J Ob-stet Gynecol 1987;157:1059–1063.Google Scholar
  28. 28.
    Humpel M, Wendt H, Pommerenke G, et al. Investigations of pharmacokinetics of levonorgestrel to specific considerations of a possible first pass effect in women. Contraception 1978;17:207–212.PubMedCrossRefGoogle Scholar
  29. 29.
    Ottosson UB, Johansson BG, Von Schoultz B. Subfractions of high density lipoprotein cholesterol during estrogen replacement: a comparison between progestogens and natural progesterone. Am J Obstet Gynecol 1985;151:746–750.PubMedGoogle Scholar
  30. 30.
    Glueck CJ, Levy RI, Fredrickson DS. Norethindrone acetate, post-heparin lipolytic activity and plasma triglycerides in types I, III, IV and V: studies in 20 patients and 5 normal persons. Ann Intern Med 1971;75:345–352.PubMedGoogle Scholar
  31. 31.
    Kim H, Kalkhoff RK. Sex steroid influence on triglyceride metabolism. J Clin Invest 1975; 56: 888–896.PubMedCrossRefGoogle Scholar
  32. 32.
    Tikkanen MJ, Nikkila EA. Regulation of hepatic lipase and serum lipoproteins by sex steroids. Am Heart J 1987;113:562–567.PubMedCrossRefGoogle Scholar
  33. 33.
    Khokha R, Huff MW, Wolfe BM. Divergent effects of d-norgestrel on the metabolism of rat very low density and low density apoliproteins. J Lipid Res 1986;27:699–705.PubMedGoogle Scholar
  34. 34.
    Oral Contraceptives. Med Lett 1988;30:106. Google Scholar
  35. 35.
    Albers JJ, Warnick GR, Nichols AV. Laboratory measurement of HDL. In: Miller TSHE, Miller GJ, eds. Clinical and Metabolic Aspects of High-Density Lipoproteins. Amsterdam: Elsevier, 1984:381–387.Google Scholar
  36. 36.
    Lipson A, Stoy DB, LaRosa JC, et al. Progestins and oral contraceptive-induced lipoprotein changes: a prospective study. Contraception 1986;34:121–134.PubMedCrossRefGoogle Scholar
  37. 37.
    Powell MC, Hedlin AM, Cerskus I, et al. Effects of oral contraceptives on lipoprotein lipids: a prospective study. Obstet Gynecol 1947;63:764–770.Google Scholar
  38. 38.
    Burkman RT, Robinson JC, Kruszon-Moran D, et al. Lipid and lipoprotein changes associated with oral contraceptive use; a randomized clinical trial. Obstet Gynecol 1988;71:33–38.PubMedGoogle Scholar
  39. 39.
    Krauss RM, Roy S, Mishell DR Jr, et al. Effects of two low-dose oral contraceptives on serum lipids and lipoproteins: different changes in high-density lipoprotein subclasses. Am J Obstet Gynecol 1183;145:446–452.Google Scholar
  40. 40.
    Percival-Smith RKL, Morrison BJ, Sizto R, et al. The effects of triphasic and biphasic oral contraceptive preparations on HDL cholesterol and LDL cholesterol in young women. Contraception 1987;35:179–187.PubMedCrossRefGoogle Scholar
  41. 41.
    Harvengt C, Desager JP, Gaspard U, et al. Changes in lipoprotein composition in women receiving two low-dose oral contraceptives containing ethinyl estradiol and gonane progestins. Contraception 1988;37:565–575.PubMedCrossRefGoogle Scholar
  42. 42.
    Kloosterboer HJ, van Wayjen RGA, van den Ende A. Comparative effects of monophasic desogestrel plus ethinyloestradiol and triphasic levonorgestrel plus ethinyloestradiol on lipid metabolism. Contraception 1986;34:135–144.PubMedCrossRefGoogle Scholar
  43. 43.
    Gaspard UJ, Buret J, Gillian D, et al. Serum lipid and lipoprotein changes induced by new oral contraceptives containing ethinyl estradiol plus levonorgestrel or desogestrel. Contraception 1984;31:395–408.CrossRefGoogle Scholar
  44. 44.
    Marz W, Gross W, Gahn G, et al. A randomized crossover comparison of two low-dose contraceptives: effects on serum lipids and lipoproteins. Am J Obstet Gynecol 1985;153:287–293.PubMedGoogle Scholar
  45. 45.
    Whitehead MI, King RJB, McQueen J, et al. Endometrial histology and biochemistry in climacteric women during oestrogen and oestrogen/progestin therapy. J R Soc Med 1979;73:322–327.Google Scholar
  46. 46.
    Lindsay R, Hart DM, Forrest C, et al. Prevention of spinal osteoporosis in oophorectomized women. Lancet 1980;2:1151–1154.PubMedCrossRefGoogle Scholar
  47. 47.
    Muesing RA, Miller VT, LaRosa JC. Quantitative and qualitative effects of unopposed estrogen on HDL subproteins and apoproteins in 30 postmenopausal women. In preparation, 1990.Google Scholar
  48. 48.
    Hart DM, Farish E, Fletcher CD, et al. Ten years postmenopause hormone replacement therapy—effect on lipoproteins. Maturitas 1984;5:271–276.PubMedCrossRefGoogle Scholar
  49. 49.
    Bradley DD, Wingerd J, Petitti DB, et al. Serum high-density-lipoprotein cholesterol in women using oral contraceptives, estrogen and progestins. N Engl J Med 1978;299:17–20.PubMedCrossRefGoogle Scholar
  50. 50.
    Wallentin L, Larsson-Cohn V. Metabolic and hormonal effects of postmenopausal oestrogen replacement therapy treatment. II. Plasma lipids. Acta Endocrinol (Copenh) 1977;86:597–607.Google Scholar
  51. 51.
    Blumenfeld Z, Aviram B, Brook GJ, et al. Changes in lipoproteins and sub-fractions following oophorectomy and estrogen replacement in perimenopausal women. Maturitas 1983;5:77–83.PubMedCrossRefGoogle Scholar
  52. 52.
    Farish E, Fletcher CD, Hart DM, et al. The effects of conjugated equine estrogens with and without a cyclical progestogen on lipoproteins and HDL subfractions in postmenopausal women. Acta Endocrinol (Copenh) 1986; 113:123–127.Google Scholar
  53. 53.
    Cauley JA, LePorte RE, Kuller LH, et al. Menopausal estrogen use, high-density lipoprotein cholesterol subfractions and liver function. Atherosclerosis 1983;49:31–39.PubMedCrossRefGoogle Scholar
  54. 54.
    Fahraeus L, Wallentin L. High density lipoprotein subtraction during oral and cutaneous administration of 17 beta-estradiol to menopausal women. J Clin Endocrinol Metab 1983;56:797–801.PubMedCrossRefGoogle Scholar
  55. 55.
    Farish E, Fletcher CD, Hart R, et al. The effects of hormone implants on serum lipoproteins and steroid hormones in bilaterally oophorectomized women. Acta Endocrinol (Copenh) 1984;106:116–120.Google Scholar
  56. 56.
    Sharf M, Oettinger M, Lanir A, et al. Lipid and lipoprotein levels following pure estradiol implantation in postmenopausal women. Gynecol Obstet Invest 1985;19:207–212.PubMedCrossRefGoogle Scholar
  57. 57.
    Fahraeus L, Larsson-Cohn U, Wallentin L. Lipoproteins during oral and cutaneous administration of estradiol-17 beta to menopausal women. Acta Endocrinol (Kbl) 1982;101:597–602.Google Scholar
  58. 58.
    Chetkowski RJ, Meldrum DR, Steingold KA, et al. Biological effects of transdermal estradiol. N Engl J Med 1986;314:1615–1620.PubMedCrossRefGoogle Scholar
  59. 59.
    Hirvonen E, Malkonen M, Manninen V. Effects of different progestogens on lipoproteins during postmenopausal replacement therapy. N Engl J Med 1981;304:560–563.PubMedCrossRefGoogle Scholar
  60. 60.
    Whitehead MI, Townsend PT, Pryse-Davies J, et al. Effects of various type and dosages of progestogens on the postmenopausal endometrium. J Reprod Med 1982;27:539–548.PubMedGoogle Scholar
  61. 61.
    Miller VT, Muesing RA, LaRosa JC, et al. Effects in postmenopausal women of conjugated equine estrogen with and without three different progestogens on circulating lipoproteins and apoproteins. Submitted, 1990.Google Scholar
  62. 62.
    Farish E, Fletcher CD, Hart DM, et al. A long-term study of the effects of norethisterone on lipoprotein metabolism in menopausal women. Clin Chim Acta 1983;123:193–198.Google Scholar
  63. 63.
    Jensen J, Riis BJ, Str0m V, et al. Continuous estrogen-progestogen treatment and serum lipoprotein in postmenopausal women. Br J Obstet Gynaecol 1987;94:130–135.Google Scholar
  64. 64.
    Weinstein L. Efficacy of a continuous estrogen-progestin regimen in the menopausal patient. Obstet Gynecol 1987;69:929–932.PubMedGoogle Scholar
  65. 65.
    Prough SG, Aksel S, Wiebe RH, et al. Continuous estrogen/progestin therapy in the menopause. Am J Obstet Gynecol 1987;157:1449–1453.PubMedGoogle Scholar
  66. 66.
    Miller NE, Hammet F, Saltissi S, et al. Relationship of angiographically defined coronary artery disease to plasma lipoprotein subfractions and lipoproteins. Br Med J 1981;282:1741–1744.CrossRefGoogle Scholar
  67. 67.
    Avogero P, Bittolo BG, Cazzolato GE, et al. Are apolipoproteins better discriminators than lipids for atherosclerosis? Lancet 1979;1:901–903.CrossRefGoogle Scholar
  68. 68.
    Manninen V, Elo MO, Frick MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Helsinki Heart Study. JAMA 1988;260:641–651.PubMedCrossRefGoogle Scholar
  69. 69.
    Tyroler HA, Levy RI, Thorn MD, et al. High density lipoprotein cholesterol and coronary heart disease mortality: experience of white men aged 40–59 years in the U.S. Lipid Research Clinics mortality follow-up study. In: Levy RI, et al, eds. Atherosclerosis Reviews. New York: Raven Press, 1988:277–286.Google Scholar
  70. 70.
    Newman WP, Freedman DS, Voors AW, et al. Relation of serum lipoproteins and systolic blood pressure to early atherosclerosis: the Bogalusa Heart Study. N Engl J Med 1986;314:138–144.PubMedCrossRefGoogle Scholar
  71. 71.
    Kay CR. Progestogens and arterial disease: evidence from the Royal College of General Practitioners’study. Am J Obstet Gynecol 1982;142:762–765.PubMedGoogle Scholar
  72. 72.
    Hennekens CH, Evans D, Peto O. Oral contraceptive use, cigarette smoking and myocardial infarctions. Br J Fam Plann 1979;5:66–67.Google Scholar
  73. 73.
    Slone D, Shapiro S, Kaufman DW, et al. Risk of myocardial infarction in relation to current and discontinued use of oral contraceptives. N Engl J Med 1981;305:420–442.PubMedCrossRefGoogle Scholar
  74. 74.
    Stampfer MJ, Willett WC, Colditz GA, et al. A prospective study of past use of oral contraceptive agents and risk of cardiovascular disease. N Engl J Med 1988;319:1313–1317.PubMedCrossRefGoogle Scholar
  75. 75.
    Stampfer MJ, Willett WC, Colditz GA, et al. A prospective study of postmenopausal estrogen therapy and coronary heart disease. N Engl J Med 1985;313:104–109.CrossRefGoogle Scholar
  76. 76.
    Knopp RH. Cardiovascular effects of endogenous and exogenous sex hormones over a woman’s lifetime. Am J Obstet Gynecol 1988;158:1630–1643.PubMedGoogle Scholar

Copyright information

© Springer-Verlag New York Inc. 1991

Authors and Affiliations

  • Valery T. Miller
  • John C. La Rosa

There are no affiliations available

Personalised recommendations